What is Repare Therapeutics Inc.'s earnings per share (EPS)?

Repare Therapeutics Inc. (RPTX) reported diluted earnings per share of $-2.00 for fiscal year 2024. This represents a 10.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Repare Therapeutics Inc. Financials

RPTX

Source SEC Filings (10-K/10-Q) Data as of Sep 30, 2025 Currency USD FYE December

This page shows Repare Therapeutics Inc. (RPTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial health score pending refresh

We are recalculating Repare Therapeutics Inc.'s peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Piotroski F-Score Partial

2/6

Repare Therapeutics Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.90x

For every $1 of reported earnings, Repare Therapeutics Inc. generates $0.90 in operating cash flow (-$76.4M OCF vs -$84.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$91.6M

YoY+19.8%

Repare Therapeutics Inc.'s EBITDA was -$91.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 19.8% from the prior year.

Net Income

-$84.7M

YoY+9.7%

Repare Therapeutics Inc. reported -$84.7M in net income in fiscal year 2024. This represents an increase of 9.7% from the prior year.

EPS (Diluted)

$-2.00

YoY+10.3%

Repare Therapeutics Inc. earned $-2.00 per diluted share (EPS) in fiscal year 2024. This represents an increase of 10.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$76.4M

YoY+40.8%

Repare Therapeutics Inc. generated -$76.4M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 40.8% from the prior year.

Cash & Debt

$84.7M

YoY-23.9%

5Y CAGR-2.2%

Repare Therapeutics Inc. held $84.7M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

43M

YoY+0.8%

Repare Therapeutics Inc. had 43M shares outstanding in fiscal year 2024. This represents an increase of 0.8% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-56.0%

YoY-11.8pp

Repare Therapeutics Inc.'s ROE was -56.0% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 11.8 percentage points from the prior year.

Capital Allocation

R&D Spending

$115.9M

YoY-13.2%

5Y CAGR+40.7%

Repare Therapeutics Inc. invested $115.9M in research and development in fiscal year 2024. This represents a decrease of 13.2% from the prior year.

Share Buybacks

N/A

Capital Expenditures

YoY-100.0%

Repare Therapeutics Inc. invested $0 in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 100.0% from the prior year.

RPTX Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$115.9M-13.2%	$133.6M+12.2%	$119.1M+32.2%	$90.0M+124.6%	$40.1M+91.0%	$21.0M
SG&A Expenses	$29.7M-12.1%	$33.8M+3.7%	$32.6M+24.2%	$26.2M+82.7%	$14.3M+166.6%	$5.4M
Operating Income	-$93.5M+19.5%	-$116.2M-487.1%	-$19.8M+81.8%	-$108.7M-100.1%	-$54.3M-105.9%	-$26.4M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$1.4M+115.3%	-$9.4M-161.9%	$15.1M+1002.7%	-$1.7M-26.6%	-$1.3M-779.5%	$195K
Net Income	-$84.7M+9.7%	-$93.8M-222.9%	-$29.0M+72.8%	-$106.9M-100.1%	-$53.4M-96.3%	-$27.2M
EPS (Diluted)	$-2.00+10.3%	$-2.23-223.2%	$-0.69+75.6%	$-2.83	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$7.5M-47.5%	$14.3M-29.5%	$20.3M	N/A	$28.4M-5.6%	$30.1M-8.8%	$33.0M	N/A
SG&A Expenses	$4.5M-24.6%	$6.0M-21.2%	$7.7M	N/A	$6.4M-22.5%	$8.3M-3.5%	$8.6M	N/A
Operating Income	$1.1M+106.4%	-$17.8M+43.0%	-$31.2M	N/A	-$36.4M+2.5%	-$37.3M-445.0%	$10.8M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$145K-41.5%	$248K-33.0%	$370K	N/A	$485K+48.8%	$326K-48.2%	$629K	N/A
Net Income	$3.3M+119.5%	-$16.7M+44.3%	-$30.0M	N/A	-$34.4M+1.1%	-$34.8M-364.2%	$13.2M	N/A
EPS (Diluted)	$0.08+120.5%	$-0.39+45.1%	$-0.71	N/A	$-0.81+1.2%	$-0.82-373.3%	$0.30	N/A

RPTX Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$176.5M-30.5%	$253.9M-30.3%	$364.1M-1.3%	$368.7M+3.3%	$357.1M+247.7%	$102.7M
Current Assets	$171.1M-29.8%	$243.7M-31.2%	$354.0M+0.7%	$351.4M+1.4%	$346.6M+251.6%	$98.6M
Cash & Equivalents	$84.7M-23.9%	$111.3M-30.2%	$159.5M-52.3%	$334.4M+2.5%	$326.4M+244.3%	$94.8M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$25.4M-39.3%	$41.8M-50.5%	$84.6M+5.3%	$80.3M+14.3%	$70.3M-52.8%	$148.8M
Current Liabilities	$25.3M-35.3%	$39.1M-50.3%	$78.6M+124.1%	$35.1M+218.6%	$11.0M+159.4%	$4.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$151.1M-28.7%	$212.1M-24.1%	$279.5M-3.1%	$288.4M+0.6%	$286.8M+721.8%	-$46.1M
Retained Earnings	-$417.8M-25.4%	-$333.1M-39.2%	-$239.3M-13.8%	-$210.3M-103.4%	-$103.4M-107.0%	-$49.9M

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$126.7M-2.9%	$130.5M-9.4%	$144.0M-18.4%	$176.5M-14.5%	$206.4M-12.3%	$235.3M-10.5%	$263.1M+3.6%	$253.9M
Current Assets	$124.4M-1.7%	$126.6M-9.8%	$140.3M-18.0%	$171.1M-14.6%	$200.4M-12.3%	$228.5M-10.3%	$254.7M+4.5%	$243.7M
Cash & Equivalents	$72.8M+7.6%	$67.7M-19.9%	$84.5M-0.3%	$84.7M+5.2%	$80.5M+0.9%	$79.8M-22.7%	$103.2M-7.2%	$111.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$11.6M-42.1%	$20.1M+6.1%	$18.9M-25.4%	$25.4M-19.3%	$31.4M-0.7%	$31.7M+1.7%	$31.1M-25.6%	$41.8M
Current Liabilities	$11.6M-42.1%	$20.1M+6.1%	$18.9M-25.2%	$25.3M-18.6%	$31.1M-1.2%	$31.4M+2.9%	$30.6M-21.8%	$39.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$115.1M+4.3%	$110.4M-11.7%	$125.1M-17.2%	$151.1M-13.6%	$175.0M-14.1%	$203.7M-12.2%	$232.0M+9.4%	$212.1M
Retained Earnings	-$461.3M+0.7%	-$464.6M-3.7%	-$447.8M-7.2%	-$417.8M-7.4%	-$389.1M-9.7%	-$354.7M-10.9%	-$319.9M+4.0%	-$333.1M

RPTX Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$76.4M+39.9%	-$127.2M-39590.1%	$322K+100.4%	-$85.8M-1310.2%	-$6.1M+67.0%	-$18.4M
Capital Expenditures	$0-100.0%	$1.9M+221.9%	$602K-64.4%	$1.7M-24.5%	$2.2M+71.5%	$1.3M
Free Cash Flow	-$76.4M+40.8%	-$129.1M-46005.7%	-$280K+99.7%	-$87.5M-951.4%	-$8.3M+57.8%	-$19.7M
Investing Cash Flow	$49.5M-36.6%	$78.0M+144.4%	-$175.8M-10387.9%	-$1.7M+82.8%	-$9.8M-648.7%	-$1.3M
Financing Cash Flow	$542K-35.6%	$842K-4.3%	$880K-99.1%	$95.6M-61.4%	$247.8M+140.1%	$103.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	$2.7M+116.2%	-$16.3M+43.9%	-$29.1M-6.6%	-$27.3M+10.5%	-$30.5M-0.1%	-$30.5M-355.7%	$11.9M+142.4%	-$28.2M
Capital Expenditures	N/A	N/A	N/A	$0	$0	$0	$0-100.0%	$398K
Free Cash Flow	N/A	N/A	N/A	-$27.3M+10.5%	-$30.5M-0.1%	-$30.5M-355.7%	$11.9M+141.8%	-$28.6M
Investing Cash Flow	$2.5M+532.9%	-$586K-102.0%	$28.8M-8.8%	$31.6M+1.6%	$31.1M+336.6%	$7.1M+135.0%	-$20.3M-163.7%	$31.9M
Financing Cash Flow	$30K	$0-100.0%	$79K+7800.0%	$1K-99.4%	$166K	$0-100.0%	$375K+257.1%	$105K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

RPTX Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-56.0%-11.8pp	-44.2%-33.8pp	-10.4%+26.7pp	-37.1%-18.4pp	-18.6%	N/A
Return on Assets	-48.0%-11.0pp	-36.9%-29.0pp	-8.0%+21.0pp	-29.0%-14.0pp	-15.0%+11.5pp	-26.5%
Current Ratio	6.77+0.5	6.24+1.7	4.50-5.5	10.01-21.4	31.46+8.2	23.22
Debt-to-Equity	0.17-0.0	0.20-0.1	0.30+0.0	0.28+0.0	0.24+3.5	-3.23
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	2.8%+18.0pp	-15.2%+8.8pp	-24.0%	N/A	-19.7%-2.6pp	-17.1%-22.7pp	5.7%	N/A
Return on Assets	2.6%+15.4pp	-12.8%+8.0pp	-20.9%	N/A	-16.7%-1.9pp	-14.8%-19.8pp	5.0%	N/A
Current Ratio	10.71+4.4	6.30-1.1	7.42+0.6	6.77+0.3	6.45-0.8	7.27-1.1	8.33+2.1	6.24
Debt-to-Equity	0.10-0.1	0.18+0.0	0.15-0.0	0.17-0.0	0.18+0.0	0.16+0.0	0.13-0.1	0.20
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Adicet Bio Inc ACET

$78.7M

Atara Biotherape ATRA

$73.6M

CEL-SCI Corp CVM

$20.8M

Igm Biosciences, Inc. IGMS

$76.6M

Beyondspring Inc BYSI

$44.4M

Frequently Asked Questions

Is Repare Therapeutics Inc. profitable?

No, Repare Therapeutics Inc. (RPTX) reported a net income of -$84.7M in fiscal year 2024.

What is Repare Therapeutics Inc.'s EBITDA?

Repare Therapeutics Inc. (RPTX) had EBITDA of -$91.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Repare Therapeutics Inc.'s return on equity (ROE)?

Repare Therapeutics Inc. (RPTX) has a return on equity of -56.0% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Repare Therapeutics Inc.'s free cash flow?

Repare Therapeutics Inc. (RPTX) generated -$76.4M in free cash flow during fiscal year 2024. This represents a 40.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Repare Therapeutics Inc.'s operating cash flow?

Repare Therapeutics Inc. (RPTX) generated -$76.4M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Repare Therapeutics Inc.'s total assets?

Repare Therapeutics Inc. (RPTX) had $176.5M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Repare Therapeutics Inc.'s capital expenditures?

Repare Therapeutics Inc. (RPTX) invested $0 in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Repare Therapeutics Inc. spend on research and development?

Repare Therapeutics Inc. (RPTX) invested $115.9M in research and development during fiscal year 2024.

How many shares does Repare Therapeutics Inc. have outstanding?

Repare Therapeutics Inc. (RPTX) had 43M shares outstanding as of fiscal year 2024.

What is Repare Therapeutics Inc.'s current ratio?

Repare Therapeutics Inc. (RPTX) had a current ratio of 6.77 as of fiscal year 2024, which is generally considered healthy.

What is Repare Therapeutics Inc.'s debt-to-equity ratio?

Repare Therapeutics Inc. (RPTX) had a debt-to-equity ratio of 0.17 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Repare Therapeutics Inc.'s return on assets (ROA)?

Repare Therapeutics Inc. (RPTX) had a return on assets of -48.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Repare Therapeutics Inc.'s cash runway?

Based on fiscal year 2024 data, Repare Therapeutics Inc. (RPTX) had $84.7M in cash against an annual operating cash burn of $76.4M. This gives an estimated cash runway of approximately 13 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Repare Therapeutics Inc.'s Piotroski F-Score?

Repare Therapeutics Inc. (RPTX) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Repare Therapeutics Inc.'s earnings high quality?

Repare Therapeutics Inc. (RPTX) has an earnings quality ratio of 0.90x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.